Immunocore Holdings (IMCR) Research & Development (2021 - 2026)

Immunocore Holdings (IMCR) has reported Research & Development for 6 consecutive years, with $61.1 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 8.23% year-over-year to $61.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $279.5 million (up 26.39% YoY) and the FY2025 annual result came in at $274.9 million, up 23.73% from the prior year.
• Research & Development slipped to $61.1 million in Q1 2026 per IMCR's latest filing, from $78.8 million in the prior quarter.
• Over the last five years, Research & Development for IMCR reached as high as $78.8 million in Q4 2025 and fell as low as $25.4 million in Q2 2022.
• A 5-year average of $50.4 million and a median of $51.9 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 57.49% — and 2025, when it retreated 1.72%.
• Year by year, Research & Development stood at $31.8 million in 2022, then soared by 43.15% to $45.6 million in 2023, then surged by 33.55% to $60.8 million in 2024, then increased by 29.53% to $78.8 million in 2025, then declined by 22.47% to $61.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $61.1 million, $78.8 million, and $70.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.